Oppenheimer assumed coverage on shares of Cue Biopharma (NASDAQ:CUE) in a report published on Monday, BenzingaRatingsTable reports. The firm issued an outperform rating and a $27.00 price target on the stock. Oppenheimer also issued estimates for Cue Biopharma’s Q4 2019 earnings at ($0.32) EPS, FY2019 earnings at ($1.58) EPS, Q1 2020 earnings at ($0.35) EPS, Q2 2020 earnings at ($0.36) EPS, Q3 2020 earnings at ($0.35) EPS, Q4 2020 earnings at ($0.39) EPS, FY2020 earnings at ($1.45) EPS, FY2021 earnings at ($1.63) EPS, FY2022 earnings at ($1.71) EPS, FY2023 earnings at ($1.72) EPS and FY2024 earnings at ($1.43) EPS.
Several other analysts also recently issued reports on the company. BTIG Research started coverage on Cue Biopharma in a research note on Tuesday, January 28th. They set a buy rating for the company. JMP Securities began coverage on Cue Biopharma in a research note on Wednesday, January 22nd. They set an outperform rating for the company. Zacks Investment Research cut Cue Biopharma from a strong-buy rating to a hold rating in a research report on Tuesday, January 14th. Finally, ValuEngine cut Cue Biopharma from a hold rating to a sell rating in a research report on Wednesday, November 13th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company’s stock. The company presently has an average rating of Buy and an average price target of $16.67.
CUE opened at $17.85 on Monday. The company has a market cap of $434.13 million, a PE ratio of -9.44 and a beta of 1.66. The stock has a 50-day moving average of $16.86 and a 200-day moving average of $11.75. Cue Biopharma has a 52-week low of $6.23 and a 52-week high of $21.25. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.17 and a current ratio of 3.17.
In related news, Director Christopher A. Marlett sold 20,732 shares of the business’s stock in a transaction dated Tuesday, December 17th. The stock was sold at an average price of $15.73, for a total transaction of $326,114.36. Following the completion of the transaction, the director now owns 9,000 shares of the company’s stock, valued at approximately $141,570. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Christopher A. Marlett sold 4,000 shares of the business’s stock in a transaction dated Thursday, December 19th. The stock was sold at an average price of $17.00, for a total value of $68,000.00. Following the transaction, the director now directly owns 9,000 shares of the company’s stock, valued at approximately $153,000. The disclosure for this sale can be found here. Insiders have sold a total of 42,732 shares of company stock valued at $690,664 in the last three months. 16.80% of the stock is owned by insiders.
A number of institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC raised its holdings in Cue Biopharma by 24.9% in the 4th quarter. Geode Capital Management LLC now owns 263,206 shares of the company’s stock valued at $4,178,000 after acquiring an additional 52,472 shares in the last quarter. Voss Capital LLC acquired a new position in Cue Biopharma in the 4th quarter valued at approximately $1,469,000. Bank of New York Mellon Corp raised its holdings in Cue Biopharma by 18.2% in the 4th quarter. Bank of New York Mellon Corp now owns 66,282 shares of the company’s stock valued at $1,052,000 after acquiring an additional 10,183 shares in the last quarter. UBS Group AG raised its holdings in Cue Biopharma by 21.3% in the 4th quarter. UBS Group AG now owns 58,823 shares of the company’s stock valued at $933,000 after acquiring an additional 10,310 shares in the last quarter. Finally, Renaissance Technologies LLC acquired a new position in Cue Biopharma in the 4th quarter valued at approximately $689,000. 45.93% of the stock is owned by hedge funds and other institutional investors.
About Cue Biopharma
Cue Biopharma, Inc, a biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate CUE-101, a protein biologic designed to target and activate antigen-specific T cells for human papilloma virus driven cancers.
Receive News & Ratings for Cue Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cue Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.